Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer
PR Newswire —
Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight's treatment platform No patient safety issues were reported The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®)...